What is the role of mycophenolate mofetil (MMF) in the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS)?

Updated: Dec 04, 2020
  • Author: Eric S Rovner, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print

Studies of immune modulators not evaluated in the AUA guidelines can be found in primary literature. These include mycophenolate mofetil (MMF), tanezumab, and certolizumab pegol. [71, 72]  Data on MMF are sparse, and the response was poor in patients with refractory interstitial cystitis/bladder pain syndrome (IC/BPS) in a well-done controlled trial. [73]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!